Opinion on Oncology in Europe

Published within

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

Type Product title / description Pub Price
Expert View
Expert View

ASCO meeting 2009: current blockbusters advance standard care in new indications

Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.

Published By Datamonitor
11 Jun 2009
CommentWire
CommentWire

Cell Therapeutics: pixantrone close to extending lymphoma treatment options

Having reported positive follow-up results for pixantrone from the pivotal Phase III EXTEND trial, Cell Therapeutics has now submitted a marketing application with the FDA for the drug in relapsed/refractory, aggressive non-Hodgkin's lymphoma. Pixantrone's chance of approval looks promising as it addresses an important unmet need for more effective third-line therapies in this population.

Published By Datamonitor
24 Jun 2009
CommentWire
CommentWire

Pfizer: development setbacks cast doubt over Sutent

For the third time in 2009, Pfizer has terminated a Phase III study of Sutent, this time in metastatic colorectal cancer. Although the drug remains likely to achieve blockbuster sales within its existing approved indications, this latest setback casts further doubt over its clinical potential in larger, more lucrative indications.

Published By Datamonitor
02 Jul 2009
CommentWire
CommentWire

Meda/BioDelivery Sciences: Onsolis set to break into US market

Meda's and BioDelivery Sciences' Onsolis has received approval from the FDA for the management of breakthrough pain in cancer patients. Although Onsolis faces strong competition from Fentora in the US, Datamonitor expects the product's alternative delivery system to be preferable for some patient groups. Furthermore, Datamonitor expects the companies to focus on the underdeveloped EU market.

Published By Datamonitor
17 Jul 2009
CommentWire
CommentWire

Noven: Mesafem emerges as potential alternative to HRT

Recently announced results suggest that Noven's non-hormonal therapy Mesafem is effective in relieving vasomotor symptoms associated with the menopause. However, Datamonitor believes that Mesafem will have to demonstrate equivalent or superior efficacy to hormonal replacement therapy if it is to overcome the challenges in this underserved market.

Published By Datamonitor
17 Jul 2009
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

GSK: proposal for Hycamtin approval may restrict alternative treatment options

The UK's National Institute of Health and Clinical Excellence has proposed that GlaxoSmithKline's Hycamtin be used in combination with cisplatin in women with stage IVb cervical cancer only if they have not previously received cisplatin. The health authority's decision is likely to restrict Hycamtin's use further and limit the number of treatment options available for advanced cervical cancer.

Published By Datamonitor
14 Sep 2009
Expert View
Expert View

ESMO 2009: findings confirm adjuvant use of aromatase inhibitors in early breast cancer

Positive data from the TEAM study, which is the largest of three trials investigating use of aromatase inhibitors in adjuvant breast cancer, confirmed what the oncology community already knows: adjuvant Aromasin is superior to tamoxifen in early-stage breast cancer. Despite these findings, however, Aromasin is unlikely to oust Arimidex as the leading aromatase inhibitor.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2009: novel 'super-selective' agent shows early signs of efficacy in metastatic melanoma

Phase I data for the orally available novel BRAF inhibitor PLX4032 presented at the European Society for Medical Oncology Congress 2009 are causing cautious excitement in the melanoma market. This step towards personalized cancer care has the potential to revolutionize treatment of this tumor type, but only if early efficacy signals are carried through to the end of late-phase clinical studies.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2009: new lease of life for Vectibix in colorectal cancer?

Results from two Phase III studies presented at the European Society for Medical Oncology Congress 2009 show statistically significant benefits via the addition of Vectibix to both first- and second-line chemotherapy for wild-type KRAS metastatic colorectal cancer. These positive data could help Vectibix to overcome Erbitux's first-to-market status and usurp its current position.

Published By Datamonitor
30 Sep 2009

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

No help is available.